One Drop

A2A Pharmaceuticals is a New York-based company that utilizes proprietary computational systems, including artificial intelligence, to expedite the development of innovative drug alternatives for life-threatening diseases such as cancer, bacterial infections, and muscular dystrophy. The company has achieved significant milestones, including partnerships with DAEWOONG Pharmaceutical and Insilico Medicine, as well as raising $55 million for its BIOMEA FUSION spin-off company focused on MLL-Menin and securing seed funding through SOSV and incubation at IndieBio.Generated from the website

Escala Therapeutics Inc, based in New York, NY, is a biopharmaceutical company that operates under the umbrella of Fortress Biotech, Inc. They specialize in developing a diverse pipeline of revenue-generating pharmaceutical products and development-stage product candidates, with a focus on therapeutic areas such as oncology, hematology, gene therapy, neurology, pain management, rare diseases, infectious diseases, dermatology, CNS disorders, and rheumatology. With over 25 programs in development across their partner companies, Escala Therapeutics is dedicated to providing novel therapies and solutions for patients in need. Their portfolio includes both commercial-stage products and late-stage product candidates, demonstrating their commitment to advancing healthcare through innovative drug development and strategic partnerships.Generated from the website

Turnstone Biologics is a New York-based biotechnology company focused on developing innovative therapies to treat and cure patients with solid tumors. Their mission is to address the challenge of low numbers of tumor-reactive T cells by pioneering a differentiated approach to tumor infiltrating lymphocytes (TILs). With a seasoned management team and a distinguished Scientific Advisory Board, Turnstone is dedicated to advancing the field of immunotherapy and improving outcomes for patients with solid tumors. Turnstone Biologics is committed to developing next-generation TIL therapies, known as Selected TILs, for potential treatment across multiple solid tumors. Led by President and CEO Dr. Sammy Farah, the company brings together world-renowned professionals with deep expertise in TILs, cell therapy, tumor immunology, and biologics development. With a focus on innovation and collaboration, Turnstone is at the forefront of the fight against solid tumors, aiming to deliver on the promise of curative immunotherapies.Generated from the website